Pyrazolo 4,3-c pyridines, a process for their preparation and their use as serotonin reuptake inhibitors

Abstract: The invention relates to compounds of the frmula wherein Ar is or pyridyl; R₁ is H,-(CH₂) p NR₂R₃, R₂ is hydrogen or loweralkyl; R₃ is hydrogen or loweralkyl; R₄ is hydrogen or loweralkyl; X and Y are independently halogen, trifluoromethyl, nitro, loweralkyl, loweralkoxy or hydroxy; n is 0, 1, 2 or 3; m is 0, 1 or 2; p and q are independently 2, 3 or 4; or a pharmaceutically acceptable addition salt and/or hydrate thereof, or where applicable, a geometric or optical isomer or racemic mixture thereof. This invention also relates to a process for making the compounds and to pharmaceutical compositions, and to their use as serotonin reuptake inhibitors.

Description: The present invention relates to pyrazolo[4,3-c]pyridines, a process for their preparation and their use as serotonin reuptake inhibitors EP-A- 470 039 describes 3-arylindazole derivatives with serotonin S 2 (5-HT 2 ) antagonistic activity and their use in the treatment of, inter alia, depression. Chem. Abs. 1977, 86 : 43700 Ow describes 3-phenyl indazoles as having, inter alia, antidepressant activities. J. Mol. struct., 1987, 158 , 99-108 describes the compound 3-phenylpyrazolo-(4,3-c)pyridine. The present invention provides compounds of the general formula wherein R 1 is ―(CH 2 ) p NR 2 R 3 , R 2 is hydrogen or (C 1 -C 6 )-alkyl; R 3 is hydrogen or (C 1 -C 6 )-alkyl; X and Y are independently halogen, trifluoromethyl, (C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkoxy, nitro, or hydroxy; n is 0, 1, 2 or 3; m is 0, 1 or 2; p is 2, 3 or 4; or a pharmaceutically acceptable addition salt and/or hydrate thereof, or where applicable, a geometric or optical isomer or racemic mixture thereof. This invention also relates to a process for making the compounds and to pharmaceutical compositions, and methods of use as serotonin reuptake inhibitors. The compounds of this invention are useful as serotonin reuptake inhibitors and as such may be useful for the treatment of depression, obsessive-compulsive disorders, stuttering and trichotillomania. Unless otherwise stated or indicated, the following definitions shall apply throughout the specification and appended claims. The term lower or (C 1 -C 6 ) shall mean the group it is describing contains from 1 to 6 carbon atoms. The term loweralkyl or (C 1 -C 6 )alkyl shall mean a straight or branched alkyl group having from 1 to 6 carbon atoms, e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, secbutyl, t-butyl, pentyl and hexyl. The term halogen shall mean fluorine, chlorine, bromine or iodine. Throughout the specification and amended claims, a given chemical formula or name shall encompass all stereo and optical isomers where such isomers exist. Additionally, a given chemical formula or name shall encompass pharmaceutically acceptable addition salts thereof and solvates thereof, such as hydrates. In a preferred embodiment of this invention are compounds of the formula wherein X and Y are independently hydrogen, halogen, trifluoromethyl, loweralkyl, loweralkoxy, nitro or hydroxy; n is 1, 2 or 3; m is 1 or 2; and p is 2, 3 or 4. More preferably, X is hydrogen, halogen, loweralkyl, loweralkoxy, trifluoromethyl or nitro and Y is hydrogen, halogen, loweralkyl, loweralkoxy or trifluoromethyl. Most preferable are compounds wherein X is Cl, Br, F, 4-CF 3 , 2-CH 3 , 4-NO 2 or 2-OCH 3 ; and Y is hydrogen or Cl. In another preferred embodiment of the invention are compounds of the formula wherein X and Y are independently hydrogen, halogen or CF 3 . More preferably X is halogen or CF 3 and Y is hydrogen or halogen. Most preferable are compounds wherein X is Br or Cl and Y is hydrogen. The compounds of this invention are prepared in the following manner. The substituents X, Y, R 1 , R 2 , R 3 , R 4 , n, m and p are as defined above unless indicated otherwise. PREPARATION 4-Chloropyridine of the formula is reacted with a solution of lithium diisopropylamine and tetrahydrofuran. This reaction typically takes place in a solution of tetrahydrofuran or other suitable solvent at a temperature of -80 to ―40°C for 2 to 6 hours. After stirring for 2 to 6 hours, a solution of a benzaldehyde or substituted benzaldehyde in tetrahydrofuran is added to give a compound of the formula Compound VI in suspension with toluene or other suitable solvents and an oxidizing agent such as manganese (IV) oxide is refluxed for 1 to 4 hours to give compound VII of the formula Compound VII is subsequently treated with hydrazine hydrate and refluxed for 1 to 4 hours to yield a compound VIII of the formula To prepare compound II of the formula where X, Y, n, m and p are as previously defined, compound VIII in suspension with dimethylformamide or other suitable liquid is reacted with a 2-haloalkylphthalimide and a strong base such as potassium carbonate, sodium hydride or potassium t-butoxide. This mixture is reacted, with stirring, for 1 to 10 hours at 25 to 100°C to give the phthalimido (alkyl) pyrazole pyridine of the formula Compound IX is subsequently warmed in hydrazine hydrate to remove the phthalimide moiety to yield the desired compound. To prepare compound X of the formula where R 2 and R 3 are loweralkyl, compound VIII is suspended in DMF or other suitable liquid and a strong base such as sodium hydride, potassium carbonate or potassium t-butoxide. After stirring for 30 to 120 minutes, a dialkylaminoalkyl chloride is added and the solvent is warmed to 25 to 100°C with continued stirring. After 1 to 6 hours, compound X is formed. To prepare compound XI of the formula where R 3 is loweralkyl, compound II is reacted with methyl trifluoroacetate and a non-nucleophilic base such as triethylamine to yield compound XII of the formula Compound XII with potassium t-butoxide or other suitable base is treated with dimethylsulfate or other suitable alkylating agent to yield compound XIII of the formula This reaction typically takes place in a polar aprotic solvent such as tetrahydrofuran or N,N-dimethylformamide at a temperature of 0 to 50°C for 1 to 4 hours. Compound XIII is subsequently stirred in a mixture of methanol and saturated potassium carbonate solution to yield the desired compound. The compounds of the present invention may be useful for the treatment of depression and/or obsessive competitive disorder by virtue of their ability to inhibit the reuptake of serotonin. [ 3 H]-Serotonin Uptake in Rat Whole Brain and Hypothalamic Synaptosomes Some researchers have suggested that subjects with serotonergic hypofunction comprise a biochemical subgroup of depressed patients. Others claim that altered serotonergic function determines the change associated with obsessive-compulsive disorder. This activity is determined in an assay which measures [ 3 H]-serotonin uptake in rat whole brain and hypothalamic synaptosomes. The assay described below is used as a biochemical screen for potential antidepressants which block serotonin (5-hydroxy-tryptamine (5HT)) uptake. [ 3 H]-5HT transport has been characterized in the central nervous system tissue and found to be saturable, sodium and temperature-dependent, inhibited by ouabain, metabolic inhibitors, tryptamine analogs and tricyclic antidepressants. Procedure A. Animals Male CR Wistar rats (100-125 g) B Reagents 1. Krebs-Henseleit Bicarbonate Buffer, pH 7.4 (KHBB): Prepare a 1 liter batch containing the following salts. grams/l mM NaCl 6.92 118.4 KCl 0.35 4.7 MgSO 4 ·7H 2 O 0.29 1.2 KH 2 PO 4 0.16 2.2 NaHCO 3 2.10 24.9 CaCl 2 0.14 1.3 Prior to use add to 200 ml, per assay: Dextrose 2 mg/ml 11.1 Iproniazid phosphate 0.30 mg/ml 0.1 The batch is aerated for 60 minutes with 95% O 2 /5% CO 2 , the pH is checked to insure it is at 7.4 ± 0.1, then add bovine serum albumin (Sigma cat# A-7906) 1 mg/ml. 2. Filtration buffer: Make a 4 liter batch, containing the following salts: grams/4L mM NaCl 31.68 135.5 KCl 1.40 4.7 MgSO 4 ·7H 2 O 1.16 1.2 HEPES 9.54 10.0 CaCl 2 0.56 1.3 BSA 4.0 1 mg/ml Maintain on ice. 3. Sucrose solution: 0.32 M sucrose containing 5 mM HEPES and 0.1 mM EDTA; pH to 7.3 using Tris base. 4. A 0.1 mM stock solution of serotonin creatinine SO 4 is made up in 0.01 N HCl. This is used to dilute the specific activity of the radiolabeled 5HT. 5. 5-[1,2- 3 H(N)]-Hydroxytryptamine creatinine sulfate (serotonin), specific activity 20-30 Ci/mmol, is used. The final desired concentration of [ 3 H]-5HT in the assay is 50 nM. The dilution factor is 0.8. The KHBB is made up to contain 62.5 nM of [ 3 H]-5HT. Add to 100 ml of KHBB. A) 56.1 µl of 0.1mM 5HT = 56.1nM B) 0.64 nmol of [ 3 H]-5HT = 6.4nM 62.5nM 6. For most assays, a 0.5 mM stock solution of the test compound is made up initially in either 10 µl of glacial acetic acid, 100 µl DMSO or 10 µl of the recrystallization solvent, to which is added approximately 10 ml of distilled water. Compounds are initially screened in duplicate at 3 concentrations (10 -8 , 10 -7 and 10 -6 M) made up in water. For those compounds demonstrating activity at ≤10 -7 in the initial screen, EC 50 s are determined from 7 con-centrations: 10 -9 through 10 -6 . Higher or lower concentration ranges may be used depending on the potency of the compound. To ensure consistency, the standard chlomipramine is run with each assay. C. Tissue Preparation The Percoll method for preparing synaptosomes has been modified from Nagy, A., Delgado-Escueta, A.V.J. Neurochem. 43, 1114 (1984) and Dunkley, P.R., Jarvie, R.E., Heath, J.W., Kidd, G.J., Rostas, J.A.P. Brain Research 372, 115 (1986). Male Wistar rats are decapitated and the brain rapidly removed. Whole brain (minus cerebellum) is weighed and homogenized in 15 volumes of ice cold Sucrose solution using a Potter-Elvejhem homogenizer. The following procedures are performed on ice. Homogenization should be done with 4-5 up and down strokes at medium speeds (setting 4.5 to 5) to minimize synaptosome lysis. The homogenate is centrifuged at 1000 g (3000 rpm, Sorvall SS-34 rotor) for 10 minutes at 0-4°C. The supernatant is removed and approximately 10 ml per tube is carefully layered onto a discontinuous Percoll (Sigma cat# P-1644) gradient: 21% Percoll in Sucrose solution at the bottom (15 ml per tube) and 10% Percoll in the middle (10 ml; colored with a few drops of phenol red for visibility). The Percoll gradient tubes are carefully placed into a Beckman SW-28 swinging bucket rotor and spun in a Beckman XL90 ultracentrifuge using the following program: speed, 11,000 rpm (15,000 g) for 30 minutes at 4°C; slow acceleration and deceleration (acceleration setting 9; deceleration setting 3). Tubes are carefully removed, and the top layer and the top part of the middle (red) layer are discarded using a pasteur pipette. The synaptosomes are located in the white fluffy band at the interface between the 10% and 21% Percoll layers. This is carefully removed, placed in a centrifuge tube, diluted with KHBB and spun at 21,000 g (13,000 rpm, Sorvall SS-34 rotor). The pellet (synaptosomes) is resuspended in KHBB (10 vol per gram original brain wet weight; 1 brain minus cerebellum weighs approximately 1.2 g; 2.5 brains are needed per typical assay). D. Assay 800 µl KHBB with [ 3 H]-5HT 20 µl Vehicle or appropriate drug 200 µl Tissue suspension concentration 200 µl of the tissue suspension are added to each of 24 tubes (at a time) containing the 20 µl of vehicle or drug on ice. Three minutes later, 800 µl of KHBB containing [ 3 H]-5HT are added, and the tubes are vortexed. The rack containing the 24 tubes is moved from the ice bath to a water bath set at 37°C. The tubes are incubated for 5 minutes under 95% O 2 /5% CO 2 . Uptake is terminated by filtration through GF/B filter strips using a Brandel cell harvester (filter strips are presoaked in ice cold filtration buffer). Tubes are washed once with 5 ml of ice cold filtration buffer. Filter disks are placed in scintillation vials to which are added 10 ml of scintillation fluid (EcoScint). Filters are allowed to sit overnight before being counted. For each assay, 3 tubes each are incubated with 20 µl of vehicle at both 37°C and 0° C. Active uptake is the difference between cpm taken up at 37° C and 0° C. Percent inhibition at each concentration is the mean of two deteminants. IC 50 values are derived from log probit analysis using #46 Litchfield and Wilcoxon I: confidence limits of IC 50 Pharmacologic Calculation System - version 4.0. Compound 5-HT Uptake IC 50 (µM) Chlomipramine (ref.) 0.018 Fluoxetine (ref.) 0.048 1-(2-aminoethyl)-3-(2-bromophenyl)-1H-pyrazolo[4,3-c]pyridine dihydrochloride 1.53 1-(2-aminoethyl)-3-(2-methylphenyl)-1H-pyrazolo[4,3-c]pyridine 0.87 1-(2-aminoethyl)-3-(4-bromophenyl)-1H-pyrazolo[4,3-c]pyridine 0.94 1-(3-aminopropyl)-3-(4-chlorophenyl)-1H-pyrazolo[4,3-c]pyridine dimaleate 0.77 1-(2-aminoethyl)-3-(4-trifluoromethylphenyl)-1H-pyrazolo[4,3-c]pyridine maleate 1.24 1-(2-aminoethyl)-3-(2,3-dichlorophenyl)-1H-pyrazolo[4,3-c]pyridine fumarate 0.21 1-(3-aminopropyl)-3-(2,3-dichlorophenyl)-1H-pyrazolo[4,3-c]pyridine fumarate 0.41 1-(2-aminoethyl)-3-(2,4-dichlorophenyl)-1H-pyrazolo[4,3-c]pyridine fumarate 0.058 1-(4-aminobutyl)-3-(2,4-dichlorophenyl)-1H-pyrazolo[4,3-c]pyridine dimaleate 0.095 1-(2-aminoethyl)-3-(3,4-dichlorophenyl)-1H-pyrazolo[4,3-c]pyridine maleate 0.21 1-(3-aminopropyl)-3-(3,4-dichlorophenyl)-1H-pyrazolo[4,3-c]pyridine maleate 0.24 1-(2-aminoethyl)-3-(2,3,4-trichlorophenyl)-1H-pyrazolo[4,3-c]pyridine fumarate 0.049 1-(3-aminopropyl)-3-(2,3,4-trichlorophenyl)-1H-pyrazolo[4,3-c]pyridine fumarate 0.023 Antidepressant relief is achieved when the compounds of the present invention are administered to a subject requiring such treatment as an effective oral, parenteral, or intravenous dose of from 1 to 100 mg/kg of body weight per day. It is to be understood, however, that for any particular subject, specific dosage regimens should be adjusted according to the individual need and the professional judgment of the person administering or supervising the administration of the aforesaid compound. It is to be further understood that the dosages set forth herein are exemplary only. Effective quantities of the compounds of the present invention may be administered to a subject by any one of various methods, for example, orally as in capsules or tablets, parenterally in the form of sterile solutions or suspensions, and in some cases intravenously in the form of sterile solutions. The compounds of the present invention, while effective themselves, may be formulated and administered in the form of their pharmaceutically acceptable acid addition salts for purposes of stability, convenience of crystallization and increased solubility. Preferred pharmaceutically acceptable addition salts include salts of inorganic acids such as hydrochloride, hydrobromic, sulfuric, nitric, phosphoric and perchloric acids; as well as salts of organic acids such as tartaric, citric, acetic, succinic, maleic, fumaric, and oxalic acids. Effective quantities of the compounds of the present invention may be administered to a subject by any one of various methods, for example, orally as in capsules or tablets, parenterally in the form of sterile solutions or suspensions, and in some cases intravenously in the form of sterile solutions. The compounds of the present invention, while effective themselves, may be formulated and administered in the form of their pharmaceutically acceptable addition salts for purposes of stability, convenience of crystallization and increased solubility. Preferred pharmaceutically acceptable addition salts include salts of inorganic acids such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric and perchloric acids; as well as organic acids such as tartaric, citric, acetic, succinic, maleic, fumaric, and oxalic acids. The active compounds of the present invention may be administered orally, for example, with an inert diluent or with an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the compounds may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers or chewing gums. These preparations should contain at least 0.5% of active compound, but may be varied depending upon the particular form and may conveniently be between 4% to about 75% of the weight of the unit. The amount of compound present in such composition is such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present invention are prepared so that an oral dosage unit form contains between 1.0-300 mgs of active compound. The tablets, pills, capsules, troches and the like may also contain the following ingredients: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel™, corn starch and the like; a lubricant such as magnesium stearate or Sterotex®; a glidant such as colloidal silicon dioxide; and a sweetening agent such as sucrose or saccharin or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring may be added. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as fatty oil. Other dosage unit forms may contain other various materials which modify the physical form of the dosage unit, for example, as coatings. Thus tablets or pills may be coated with sugar, shellac, or other enteric coating agents. A syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors. Materials used in preparing these various compositions should be pharmaceutically pure and non-toxic in the amounts used. For the purpose of parenteral therapeutic administration, the active compounds of the invention may be incorporated into a solution or suspension. These preparations should contain at least 0.1% of the aforesaid compound, but may be varied between 0.5 and 30% of the weight thereof. The amount of active compound in such compositions is such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present invention are prepared so that a parenteral dosage unit contains between 0.5 to 100 mgs of active compound. The solutions or suspensions may also include the following components; a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic add; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic. Examples of the compounds of this invention include: 1-(2-aminoethyl)-3-phenyl-1H-pyrazolo[4,3-c]pyridine dihydrochloride; 1-[3-(dimethylamino)propyl]-3-phenyl-1H-pyrazolo[4,3-c]pyridine dihydrochloride; 1-[3-(dimethylamino)ethyl]-3-(4-chlorophenyl)-1H-pyrazolo[4,3-c]pyridine dimaleate; 1-[3-(methylamino)propyl]-3-(4-chlorophenyl)-1H-pyrazolo[4,3-c]pyridine dimaleate; 1-(2-aminoethyl)-3-(2-bromophenyl)-1H-pyrazolo[4,3-c]pyridine dihydrochloride; 1-(3-aminopropyl)-3-phenyl-1H-pyrazolo[4,3-c]pyridine dihydrochloride; 1-(3-aminopropyl)-3-(2-bromophenyl)-1H-pyrazolo[4,3-c] pyridine dihydrochloride; 1-[3-aminopropyl]-3-(4-chlorophenyl)-1H-pyrazolo[4,3-c]pyridine dimaleate; 1-[2-aminoethyl]-3-(2-chlorophenyl)-1H-pyrazolo[4,3-c]pyridine sesquifumarate; 1-[3-(dimethylamino)propyl]-3-(2-bromophenyl)-1H-pyrazolo[4,3-c]pyridine dihydrochloride hemihydrate; 1-[2-(dimethylamino)ethyl)-3-(2-bromophenyl)-1H-pyrazolo[4,3-c]pyridine dihydrochloride hydrate; 1-[2-(dimethylamino)ethyl]-3-(3-bromophenyl)-1H-pyrazolo[4,3-c]pyridine dihydrochloride sesquihydrate; 1-[3-(dimethylamino)propyl]-3-(3-bromophenyl)-1H-pyrazolo [4,3-c]pyridine dihydrochloride hemihydrate; 1-[3-(dimethylamino)propyl]-3-(4-chlorophenyl)-1H-pyrazolo[4, 3-c]pyridine dimaleate; 1-[2-(methylamino)ethyl]-3-(4-bromophenyl)-1H-pyrazolo[4,3-c] pyridine; 1-[2-(methylamino)ethyl]-3-(4-chlorophenyl)-1H-pyrazolo[4,3-c ]pyridine sesquimaleate; 1-[3-(methylamino)propyl]-3-(4-bromophenyl)-1H-pyrazolo[4,3-c]pyridine dimaleate; and 1-[3-(methylamino)propyl]-3-(2-bromophenyl)-1H-pyrazolo[4,3-c]pyridine sesquioxalate; The following examples illustrate the preparation of some of the compounds of the invention. All temperatures are given in degrees centigrade (°C) unless indicated otherwise. Example 1 1-(2-Aminoethyl)-3-phenyl-1H-pyrazolo-[4,3-c]pyridine dihydrochloride 3-Phenyl-1H-pyrazolo[4,3-c]pyridine (1.95 g) was suspended in 50 ml of dimethylformamide to which 2-bromoethylphthalimide (2.54) and K 2 CO 3 (1.4 g) had been added. This mixture was stirred and warmed at 90°C for 4 hours and then an additional 1.25 g of 2-bromoethylphthalimide and 0.7 g of K 2 CO 3 were added. After 2 more hours another 0.60 g of 2-bromoethylphthalimide and 0.4 g of K 2 CO 3 were added and stirring and heating were continued for an additional 90 minutes. At the end of this time, the reaction mixture was poured into H 2 O and the product filtered off and dried to give 2.63 of 3-phenyl-1-[2-(phthalimido)ethyl]-1H-pyrazolo[4,3-c]pyridine. The phthalimide prepared above (4.60 g) was warmed at 55°C in 20 ml of hydrazine hydrate for 1 hour. At the end of this time the mixture was distributed between H 2 O and ethyl acetate and the organic phase was separated. The aqueous phase was extracted twice more with ethyl acetate and the combined organic phase was dried and evaporated. The dihydrochloride was formed in methanol and recrystallized from methanol-diethyl ether to give 2.10 g, m.p. 295° (dec). Analysis: Calculated for C 14 H 14 N 4 ·2HCl: 54.03%C 5.18%H 18.00%N Found: 53.76%C 5.20%H 17.70%N Following a procedure similar to that described in Example 1 above, using an appropriate bromoalkylphthalimide, the following 1-(2-aminoalkyl)-3-(phenyl or substituted phenyl)-1H-pyrazolo[4,3-c]pyridines are prepared. Example 2 1-[3-(Dimethylamino)propyl]-3-phenyl-1H-pyrazolo[4,3-c]pyridine dihydrochloride 3-Phenyl-1H-pyrazolo[4,3-c]pyridine (3.90 g) was suspended in 50 ml of dimethylformamide and 60% NaH (1.0 g) was added. After stirring for 90 minutes, dimethylaminopropyl chloride (3.0 g) was added, and stirring was continued for 1 hour. At the end of this time the reaction was warmed to 55° and, after an additional 2 hours, an additional 0.50 g of dimethylaminopropyl chloride was added. Warming and stirring was continued for 1 hour, after which time the reaction mixture was distributed between ether and H 2 O. The organic phase was dried, evaporated, and purified by flash chromatography (5% triethylamine-ethyl acetate), giving an oil upon evaporation of the product-containing fractions. The hydrochloride was formed in ethereal HCl and recrystallized from methanol-ether to give 3.76 g of product, m.p. 237-239°. Analysis: Calculated for C 17 H 20 N 4 ·2HCl: 57.80%C 6.28%H 15.86%N Found: 57.76%C 6.53%H 15.70%N Example 3 1-[2-(Dimethylamino)ethyl]-3-(4-chlorophenyl)-1H-pyrazolo[4,3-c]-pyridine dimaleate A mixture of 3-(4-chlorophenyl)-1H-pyrazolo[4,3-c]pyridine (3.47 g), potassium carbonate (2.4 g) and dimethylaminoethyl chloride hydrochloride (4.6 g) in 50 ml DMF was heated at 85° C for 1 hour. The reaction was quenched into iced water and extracted three times with ethyl acetate. The combined organics were washed with water and dried (saturated NaCl, MgSO 4 ). The compound was purified via flash chromatography (5 → 10% triethylamine/ethyl acetate) to give 3.47 g of an oil. The oil was dissolved in methanol, treated with 2.1 equivalents of maleic acid and crystallized with ethyl ether to give 4.95 g of a powder, m.p. 134-136°C. Analysis: Calculated for C 16 H 17 C1N 4 ·2C 4 H 4 O 4 : 54.09%C 4.73%H 10.51%N Found: 54.07%C 4.69%H 10.45%N Following a procedure similar to that described in Example 3, using an appropriate dimethylaminoalkylchloride, the following 1-[ω-(dimethylamino)alkyl]-3- (phenyl or substituted phenyl)-1H-pyrazolo[4,3-c]pyridines are prepared. Example X Y P Salt/Hydrate m.p.( C)/Recryst. Solv. 3A 2-Br H 3 di-HCl/hemihydrate 120/methanolethyl acetate 3B 2-Br H 2 di-HCl/hydrate 207/methanol-ether 3C 3-Br H 2 di-HCl/1.5 Hydrate 134-136/methanol-ether 3D 3-Br H 3 di-HCl/hemihydrate 138-140/methanol-ether 3E 4-Cl H 3 dimaleate 129-131 (dec)/methanol-ether 3F H H 2 dimaleate 134-135/methanol-ether 3G 4-Br H 3 dimaleate 129-130/methanol-ether 3H 4-Br H 2 dimaleate 139-140/methanol ether 3I 2-Cl H 3 fumarate 156-158 (dec) methanol-ether 3J 2-Cl H 2 di-HCl/.25 hydrate 205-207/methanolethyl acetate Example 4 1-[3-Methylaminopropyl]-3-(4-chlorophenyl)-1H-pyrazolo[4,3-c]-pyridine dimaleate A mixture of 1-[3-aminopropyl]-3-(4-chlorophenyl)-1H-pyrazolo[4,3-c]pyridine dimaleate (3.3 g), methyl trifluoroacetate (1.27 ml) and triethylamine (1.9 ml) in 75 ml methanol was stirred at ambient temperature for 45 minutes. Concentration of the mixture and trituration of the resulting solid with ether gave 3.76 g of a powder, m.p. 122-125°C. A mixture of the trifluoroacetamide (3.19 g) and potassium t-butoxide (1.07 g) in 70 ml THF was treated with dimethyl sulfate (0.83 ml) After stirring at ambient temperature for 1 hour the reaction was quenched with aqueous ammonia and the aqueous was extracted three times with ethyl acetate. The combined organics were washed with water and dried (saturated NaCl, MgSO 4 ). Concentration of the solvent gave 3.6 g of a solid which was used in the next step. The methyl derivative was stirred for 45 minutes in a mixture of 50 ml methanol and 50 ml saturated potassium carbonate solution. The mixture was partitioned between ethyl acetate and water and the aqueous was extracted twice with ethyl acetate. The combined organics were dried with MgSO 4 . The desired compound was purified via flash chromatography (dichloromethane, methanol, triethylamine; 18:1:1) to give 1.11 g of an oil. This oil was dissolved in methanol treated with 2.1 equivalents of maleic acid and crystallized with ethyl ether to give 0.979 g of a powder, m.p. 149-150°C. Analysis: Calculated for C 16 H 17 ClN 4 ·2C 4 H 4 O 4 ; 54.09%C 4.73%H 10.51%N Found: 53.70%C 4.44%H 10.42%N Following a procedure similar to that described in Example 4, using an appropriate starting primary amine, the following 1-[methytaminoalkyl]-3-[substituted phenyl]-1H-pyrazolo[4,3-c]pyridines are prepared. Starting Amine Ex.# X Y P Salt/Hydrate m.p.(°C)/Recryst. Solv. Ex. 1H 4A 4-Br H 2 _ 60-61/ether-pentane Ex. 1F 4B 4-Cl H 2 1.5 maleate 169-170 (dec)/methanol-ether Ex. 1I 4C 4-Br H 3 dimaleate 153-154/methanol-ether Ex. 1C 4D 2-Br H 3 1.5 oxalate 117 (dec)/methanol-ether Ex. 1A 4E 2-Br H 2 1.5 fumarate 170-172/methanol-ether Ex. 1F 4F 3-Br H 2 _ 71-72.5/ether

Claims: A compound of the formula I wherein Ar is R 1 is-(CH 2 ) p NR 2 R 3 , R 2 is hydrogen or (C 1 -C 6 )-alkyl; R 3 is hydrogen or (C 1 -C 6 )-alkyl; X and Y are independently halogen, trifluoromethyl, (C 1 -C 6 )-alkyl; (C 1 -C 6 )-alkoxy, nitro or hydroxy; n is 0, 1, 2 or 3; m is 0, 1 or 2; p is 2, 3 or 4; or a pharmaceutically acceptable addition salt and/or hydrate thereof, or where applicable, the optical or geometric isomer or racemic mixture thereof. A compound as defined in claim 1, wherein X is F, Cl, Br, CF 3 , NO 2 , CH 3 or OCH 3 , Y is Cl, m is 0 or 1, n is 1 or 2, R 2 and R 3 are both hydrogen, an p is as defined. The compound as defined in claim 2 which is 1-(2-aminopropyl)-3-(2,3,4-trichlorophenyl)-1H-pyrazolo[4,3-c]pyridine or a pharmaceutically acceptable acid addition salt thereof. The compound as defined in claim 2 which is 1-(3-aminopropyl)-3-(2,3,4-trichlorophenyl)-1H-pyrazolo[4,3-c]pyridine or a pharmaceutically acceptable acid addition salt thereof. The compound as defined in claim 2 which is 1-(2-aminoethyl)-3-(2,4-dichlorophenyl)-1H-pyrazolo[4,3-c]pyridine or a pharmaceutically acceptable acid addition salt thereof. The compound as defined in claim 2 which is 1-(4-aminobutyl)-3-(2,4-dichlorophenyl)-1H-pyrazolo[4,3-c]pyridine or a pharmaceutically acceptable acid addition salt thereof. A pharmaceutical composition which comprises as the effective amount a compound as defined in claim 1 and a suitable carrier therefor. Use of a compound as defined in claim 1 for the preparation of a medicament having serotonin reuptake inhibiting activity. A process for the preparation of a compound as defined in claim 1, which comprises a) reacting a compound of the formula I, wherein R 1 is hydrogen, with 2-haloalkylphthalimide in the presence of a strong base, to give a compound of the formula wherein Ar and p are as defined, and warming the compound obtained in hydrazine hydrate to form a compound of the formula I, wherein R 1 is -(CH 2 ) p NH 2 , where p is as defined, or b) reacting a compound of the formula I, wherein R 1 is hydrogen, with a compound of the formula Cl(CH 2 ) p NR 2 R 3 where p, R 2 and R 3 are as defined, in the presence of a strong base, to form a compound of the formula I, wherein R 1 is ―(CH 2 ) p NR 2 R 3 , where R 2 and R 3 are (C 1 -C 6 )alkyl and p is as defined, or c) reacting a compound of the formula I, wherein R 1 is ―(CH 2 ) p NH 2 , where p is as defined, with methyl trifluoracetate, to form a compound of the formula XIIa wherein Ar and p are as defined, and reacting the compound obtained with an alkylating agent to form a compound of the formula XIIIa wherein Ar and p are as defined, and R 3 is (C 1 -C 6 )alkyl, and treating the compound obtained with an inorganic base to form a compound of the formula I, wherein R 1 is ―(CH 2 ) p NHR 3 .

Inventors: KAPPLES KEVIN J, SHUTSKE GREGORY, TOMER JOHN DICK, KAPPLES, KEVIN J., SHUTSKE, GREGORY, TOMER, JOHN DICK
Applicants: AVENTIS PHARMA INC, AVENTIS PHARMACEUTICALS INC.
Application year: 1993
Main classification: C07D471
IPC codes: A61P25, A61K31, C07D471